---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-065597"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T20:06:24.328092+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q2 sales down 9% to $3.5M; net loss widens to $1.4M from $684K

## Summary
- Product sales $3.5M in Q2 2023 vs $3.9M in Q2 2022 (-9%); gross margin fell to 30% from 44%.
- Net loss $(1.4M) or $(0.18)/share vs $(0.684M) or $(0.09)/share in prior-year quarter.
- Six-month net loss widened to $(3.7M) from $(171K); EBITDA turned negative $(2.2M) vs positive $1.2M.
- Cash dropped to $1.5M from $5.8M at Dec 31, 2022; raised $3M debt facility with 7-year amortization.
- CEO cites production contamination remediation; goal to reach ~$6M quarterly output (80% of $30M capacity).

## SEC filing metadata
- accession: 0001213900-23-065597
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/ea183184-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-065597
- JSON: https://secwatch.observer/filing/0001213900-23-065597.json
- Plain text: https://secwatch.observer/filing/0001213900-23-065597.txt

## Key facts
- Earnings Releases
  IMMUCELL CORP /DE/ reported the quarter ended June 30, 2023 results: revenue $3.5 million, net income ($1.4) million, EPS ($0.18) per basic share.
  - Period: the quarter ended June 30, 2023
  - Revenue: $3.5 million
  - Net income: ($1.4) million
  - EPS: ($0.18) per basic share
  - Result: reported results
  source text: review shortly, which is a critical milestone in our efforts to commercialize this product.” 1 of 6 Certain Financial Results: ● Product sales decreased by 9%, or $329,000, to $3.5 million during the three-month period ended June 30, 2023 compared to $3.9 million during the three-month period ended June 30, 2022. ● Product sales decreased by 29%, or $2.9 million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm
- Earnings Releases
  IMMUCELL CORP /DE/ reported the six-month period ended June 30, 2023 results: revenue $7.0 million, net income ($3.7) million, EPS ($0.48) per basic share.
  - Period: the six-month period ended June 30, 2023
  - Revenue: $7.0 million
  - Net income: ($3.7) million
  - EPS: ($0.48) per basic share
  - Result: reported results
  source text: the three-month period ended June 30, 2023 compared to $3.9 million during the three-month period ended June 30, 2022. ● Product sales decreased by 29%, or $2.9 million, to $7.0 million during the six-month period ended June 30, 2023 compared to $9.9 million during the six-month period ended June 30, 2022. ● Product sales decreased by 23%, or $4.8 million, to
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm
- Earnings Releases
  IMMUCELL CORP /DE/ reported the trailing twelve-month period ended June 30, 2023 results: revenue $15.7 million.
  - Period: the trailing twelve-month period ended June 30, 2023
  - Revenue: $15.7 million
  - Result: reported results
  source text: Product sales decreased by 23%, or $4.8 million, to $15.7 million during the trailing twelve-month period ended June 30, 2023 compared to $20.5 million during the trailing twelve-month period ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/811641/000121390023065597/0001213900-23-065597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.